In addition to conventional hypoglycemic agents and insulin, newly developed agents such as glucagon-like peptide-1 and its related peptide, dipeptidyl peptide IV, sodium-glucose cotransporter-2 (SGLT2) inhibitors, and imeglimin have improved the therapeutic strategies for the management of blood glucose levels in patients with diabetes mellitus [6,7]. This evidence concerns the gene SLC5A2 and diabetes mellitus.